Intranasal vasoactive intestinal peptide sits at the top of the published chronic inflammatory response syndrome protocol as a late-stage correction, added only after the source of ongoing inflammation has been removed, and the evidence behind it is open-label case series rather than controlled trial data. The rationale is a measured deficiency: patients meeting the syndrome's case definition were reported to carry low or undetectable serum levels of the 28 amino acid neuropeptide, alongside elevated transforming growth factor beta 1, elevated complement split product C4a, and low melanocyte stimulating hormone. For anyone weighing the cost and the sourcing risk, the distinction between a documented deficiency and a proven treatment effect is where an honest reading of this therapy starts.
Intranasal vasoactive intestinal peptide is positioned as the final corrective step of the chronic inflammatory response syndrome protocol, given at 50 micrograms per spray four times daily only after environmental exposure, resistant nasal colonization, and earlier laboratory abnormalities have been resolved.
The syndrome has a working case definition but not a recognized diagnostic one. Its proponents describe a persistent, multi-system illness following exposure to a biologically produced toxin, most often from a water-damaged building, in a person whose innate immune system never clears the antigen and settles into chronic activation. Mainstream allergy and occupational medicine bodies have published positions holding that the evidence does not support a distinct toxin-mediated syndrome of this kind, and many of the markers in the panel lack validated reference ranges for this purpose, which leaves patients paying out of pocket for a diagnostic workup that standard care does not accept.
The working case definition requires an exposure history, symptoms drawn from at least six of thirteen organ system clusters, supporting biomarker abnormalities, and relapse on re-exposure, a framework mainstream allergy and occupational medicine societies have declined to endorse as a distinct diagnosis.
The target is a measured shortfall rather than an inferred one, with serum levels in affected patients reported at or below the low end of the reference range and often under 23 picograms per milliliter. The protocol's model holds that ongoing cytokine activity suppresses hypothalamic production of the peptide, so leaving the exposure stops new insult without restoring the regulatory molecule, and that feed-forward gap is what the spray is meant to close. This is a mechanistic argument built on receptor pharmacology, not a demonstrated clinical effect.
Serum vasoactive intestinal peptide is reported at or under roughly 23 picograms per milliliter in affected patients, and replacement is theorized to restrain nuclear factor kappa B driven transcription of tumor necrosis factor alpha, interleukin 6 and interleukin 12 through VPAC1 and VPAC2 receptor signaling.
Route selection here is dictated by chemistry, not preference. The molecule is a 28 residue linear peptide with no oral bioavailability worth measuring, because gastric acid and pancreatic proteases cleave it before absorption, and parenteral dosing runs into a plasma half-life on the order of one to two minutes from ubiquitous peptidases and pulmonary first-pass extraction. The nasal mucosa offers roughly 150 square centimeters of thin, highly vascular epithelium with a lower peptidase burden than the gut and no hepatic first pass, which is what makes a small metered spray workable at all.
| Criterion | Oral | Parenteral | Intranasal |
|---|---|---|---|
| Bioavailability | Negligible; cleaved before absorption | Complete but fleeting | Meaningful local and systemic exposure |
| Clearance constraint | Not applicable, drug destroyed | 1 to 2 minute plasma half-life | Same clearance, offset by repeat mucosal dosing |
| First-pass loss | Gastric and hepatic | Pulmonary extraction | None |
| Practical form | Non-viable | Research infusion settings | 50 mcg in about 0.1 mL, four times daily |
Oral dosing is non-viable because gastric acid and pancreatic proteases cleave the 28 residue peptide before absorption, and systemic dosing faces a plasma half-life of roughly one to two minutes, which leaves a compounded intranasal spray of about 50 micrograms per actuation as the practical delivery form.
The published protocol reads as a numbered ladder of roughly a dozen steps, with the peptide spray at or near the top rung. Every rung below it is either removal of the driver or correction of a downstream abnormality, on the stated reasoning that replacement is a regulatory correction rather than a rescue. Where inflammagen is still arriving, the case series report that markers fail to move, expensive drug is consumed against an ongoing insult, and some patients flare.
The peptide spray occupies the last rung of a roughly twelve-step protocol ladder, added only after environmental removal, binder therapy, nasal decolonization and marker correction, with active treatment usually described in months rather than weeks and commonly running six to eighteen.
Readiness is treated as a gate rather than a formality, and most of those gates are documented with numbers instead of judgment calls. Environmental clearance is the least negotiable, since replacing a regulatory peptide while inflammagen keeps arriving is regarded as futile. The pancreatic enzyme check is the one condition that exists for safety rather than protocol logic.
The documented start gates are an ERMI below roughly 2 or a HERTSMI-2 below 11, a negative deep nasal culture for resistant coagulase negative staphylococci, corrected upstream markers, and a baseline serum lipase, with an elevated lipase treated as a reason not to begin.
Dosing in the published protocol is fixed at the start rather than titrated to weight: 50 micrograms per spray, one spray into one nostril four times daily, roughly 200 micrograms across the day. Response is judged on three parallel tracks, and a mismatch between them is treated as information rather than noise. A patient whose laboratory values move while symptoms hold still is not counted as helped.
The published regimen is fixed at 50 micrograms per spray four times daily, roughly 200 micrograms per day, with response tracked by serum peptide level and transforming growth factor beta 1 at about 30 days and then at one to three month intervals.
The commonly reported reactions are local and mild: nasal burning or stinging on administration, rhinorrhea, transient headache, facial flushing, and lightheadedness that tracks the peptide's vasodilator activity. The serious signal is pancreatic, since the peptide has secretory effects on pancreatic ductal tissue and a rise in serum lipase has been observed in a small number of treated patients, which is the reason enzyme testing sits in the protocol at all. Frank pancreatitis has not been documented at protocol doses in the published case series, though no long-term controlled safety studies of daily intranasal use over months exist either.
A rise in serum lipase is the documented serious signal for intranasal vasoactive intestinal peptide, reported in a small number of treated patients without frank pancreatitis at protocol doses, and no meaningful safety data exist for use in pregnancy, breastfeeding, children, or patients with malignancy.
The evidence is weak, and open-label case series is the honest label for it. The primary work describes on the order of twenty to forty treated patients with before-and-after biomarkers and symptom scores, published without blinding, randomization or a placebo arm, and nearly all of it traces back to a single investigator and closely associated collaborators. The deeper problem is attribution: by design, patients have already left the exposure, taken binders, cleared nasal colonization and corrected several other abnormalities before the spray is added, so improvement at that point has many plausible parents.
The supporting literature consists of open-label case series and retrospective cohorts of roughly twenty to forty patients from a single investigator group, with no randomized, blinded or placebo-controlled trial and no independent replication of the findings.
Availability, not efficacy, is often the practical barrier. There is no approved drug application for this indication in the United States, so every legitimate prescription has been a compounded preparation made from bulk active ingredient under section 503A of the Food, Drug, and Cosmetic Act, and the agency has left the substance in the category still under evaluation rather than moving it onto the list judged to raise significant safety risks for compounding. Cost falls entirely on the patient, because an unrecognized diagnosis is not an insurable one.
| Criterion | Compounded 503A pharmacy | Research-chemical supplier |
|---|---|---|
| Regulatory standing | Supplied under the agency's interim policy for substances under evaluation | Unapproved, unlabeled bulk powder |
| Product assurance | Pharmacy-controlled, batch consistency varies | No sterility assurance, no potency verification, no endotoxin testing |
| Monthly cost | Roughly $150 to $400 | Lower, with no recourse if the product is wrong |
| Insurance coverage | Essentially never covered | Not applicable |
A compounded intranasal preparation runs roughly 150 to 400 dollars per month with essentially no insurance coverage, on top of a specialty laboratory panel that can cost several hundred to well over a thousand dollars per draw and is repeated several times during a course.
Educational use only. This article describes what the published scientific and clinical literature reports about Vasoactive Intestinal Peptide. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
Talk to a licensed prescriber. Whether a treatment described here is appropriate for you depends on your medical history, your current medications, and the monitoring you may need. A licensed healthcare provider can evaluate your situation.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
